Compare · MSLE vs NVO
MSLE vs NVO
Side-by-side comparison of Satellos Bioscience Inc. (MSLE) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MSLE and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $208.47B, about 1001.7x MSLE ($208.1M).
- Over the past year, MSLE is down 15.2% and NVO is down 2.3% - NVO leads by 12.9 points.
- NVO has been more active in the news (6 items in the past 4 weeks vs 2 for MSLE).
- NVO has more recent analyst coverage (25 ratings vs 3 for MSLE).
- Company
- Satellos Bioscience Inc.
- Novo Nordisk A/S
- Price
- $10.08+5.33%
- $47.08-8.73%
- Market cap
- $208.1M
- $208.47B
- 1M return
- +37.33%
- -3.49%
- 1Y return
- -15.15%
- -2.28%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 6
- Recent ratings
- 3
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MSLE
- SEC Form 6-K filed by Satellos Bioscience Inc.
- Satellos Reports Six-Month Interim TRAILHEAD Data Showing Reduced Muscle Fat Fraction, Increased Effort, Stable Strength, Lower CK and Favorable Safety Profile in DMD Adults Treated with SAT-3247
- SEC Form 6-K filed by Satellos Bioscience Inc.
- Satellos Receives FDA Fast Track Designation for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
- SEC Form 6-K filed by Satellos Bioscience Inc.
- Satellos to Present Clinical Program Updates at ICNMD 2026
- SEC Form 6-K filed by Satellos Bioscience Inc.
- Satellos Bioscience Announces Results of Annual Meeting of Shareholders
- SEC Form 6-K filed by Satellos Bioscience Inc.
- Satellos to Participate in Upcoming Investor Conferences
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S